Diagnosis of Alzheimer disease based on detections of complexes of amyloid beta peptide and of some endogenous substances in cerebrospinal fluid

After developments of new highly sensitive methods (via ELISA and surface plasmon resonance biosensors) , we will evaluate the levels of two complexes of amyloid beta peptides with either mitochondrial enzyme 17beta-hydroxysteroid dehydrogenase type 10 or protein tau in cerebrospinal fluids of demented and nondemented people. The results will be compared with those of triplet (amyloid beta peptide 1-42, total tau and phospho-tau levels by means of kits).